By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS


Industry
Pharmaceutical






Company News
Ipsen (IPN.PA) Release: Endocrine Practice Publishes ELECT Phase III Trial Results In Adults With Carcinoid Syndrome 6/6/2016 8:37:58 AM
ASCO2016: Exelixis (EXEL) And Its Partner Ipsen (IPN.PA) Announce Positive Overall Survival Results From Subgroup Analyses Of Phase III Trial Of CABOMETYX (Cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting 6/6/2016 6:10:47 AM
ASCO2016: Ipsen (IPN.PA) Announces Data Presentations Of Somatuline Depot (Lanreotide) Injection In Gastroenteropancreatic Neuroendocrine Tumors At American Society Of Clinical Oncology Annual Meeting 6/3/2016 7:45:20 AM
Ipsen (IPN.PA)’s Partner Exelixis (EXEL) Announced Results From Randomized Phase 2 Trial CABOSUN That Demonstrate That Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 5/24/2016 10:59:01 AM
Ipsen (IPN.PA) Partners With Institute of Molecular and Cell Biology To Advance Understanding And Research Of Botulinum Neurotoxin Biology 5/16/2016 9:22:43 AM
Oncodesign SA And Ipsen (IPN.PA) Enter Into A Strategic Partnership In Oncology And Oncodesign Joins Ipsen’s Paris-Saclay Campus 5/3/2016 9:41:41 AM
Ipsen (IPN.PA)’s First Quarter 2016 Sales 4/28/2016 10:39:46 AM
Ipsen (IPN.PA) Is Pleased To Announce That Its Partner Exelixis (EXEL) Obtained FDA Approval Of CABOMETYX (Cabozantinib) Tablets For Patients With Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy 4/26/2016 12:42:28 PM
Probi And Ipsen (IPN.PA) Sign Extensive Primary Care Distribution Agreement For Probiotic LP299V, Lactobacillus Plantarum 299v 4/26/2016 12:40:53 PM
Carcinoid Cancer Foundation And Self Care Catalysts Inc. To Provide A Free Digital Patient Support Application For Carcinoid And Neuroendocrine Tumor (NET) Patients, Sponsored In Part By Ipsen (IPN.PA) 4/6/2016 8:08:18 AM
12345678910...
//-->